MARKET

CRMD

CRMD

Cormedix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.610
+0.340
+10.40%
After Hours: 3.610 0 0.00% 16:00 05/16 EDT
OPEN
3.360
PREV CLOSE
3.270
HIGH
3.870
LOW
3.280
VOLUME
788.54K
TURNOVER
0
52 WEEK HIGH
8.38
52 WEEK LOW
2.870
MARKET CAP
139.81M
P/E (TTM)
-4.8165
1D
5D
1M
3M
1Y
5Y
41 Stocks Moving In Monday's Mid-Day Session
Gainers Data Storage Corporation (NASDAQ: DTST) shares jumped 51.1% to $3.4750 after the company reported better-than-expected Q1 financial results.
Benzinga · 6h ago
Cormedix: Q1 Earnings Insights
Cormedix (NASDAQ:CRMD) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Cormedix beat estimated earnings by 18.18%, reporting an EPS of $-0.18 versus an estimate of ...
Benzinga · 3d ago
CorMedix GAAP EPS of -$0.18 beats by $0.04, revenue of $0.01M misses by $0.01M
CorMedix press release (NASDAQ:CRMD): Q1 GAAP EPS of -$0.18 beats by $0.04. Revenue of $0.01M (-88.9% Y/Y) misses by $0.01M. Joe Todisco, CorMedix CEO, commented, “We are very pleased to
Seekingalpha · 4d ago
CorMedix hires new CEO, makes other executive changes; new operational focus
CorMedix (NASDAQ:CRMD) hired Joe Todisco as its new CEO, effective May 10. The infectious and inflammatory diseases developer also said that Chief Commercial Officer Tom Nusbickel has left. Donna Ucci joined the Company as
Seekingalpha · 4d ago
BRIEF-CorMedix Says CEO Joe Todisco Officially Joined Organization
reuters.com · 4d ago
CorMedix Q1 2022 Earnings Preview
CorMedix (NASDAQ:CRMD) is scheduled to announce Q1 earnings results on Thursday, May 12th, after market close. The consensus EPS Estimate is -$0.22 (vs. -$0.20 last year) and the consensus Revenue Estimate
Seekingalpha · 5d ago
CorMedix Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12
BERKELEY HEIGHTS, N.J. , May 03, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, toda...
GlobeNewswire · 05/03 12:30
CorMedix Inc. to Present at the 21st Annual Needham Virtual Healthcare Conference
BERKELEY HEIGHTS, N.J., April 04, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, tod...
GlobeNewswire · 04/04 12:30
More
No Data
Learn about the latest financial forecast of CRMD. Analyze the recent business situations of Cormedix through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CRMD stock price target is 22.00 with a high estimate of 27.00 and a low estimate of 19.00.
High27.00
Average22.00
Low19.00
Current 3.610
EPS
Actual
Estimate
-0.18-0.14-0.09-0.05
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 95
Institutional Holdings: 14.20M
% Owned: 36.67%
Shares Outstanding: 38.73M
TypeInstitutionsShares
Increased
26
1.80M
New
7
83.99K
Decreased
25
462.74K
Sold Out
7
183.86K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.21%
Pharmaceuticals & Medical Research
+1.02%
Key Executives
Non-Executive Chairman/Independent Director
Myron Kaplan
Chief Executive Officer/Chief Financial Officer/Executive Vice President
Matthew David
Executive Vice President/General Counsel
Phoebe Mounts
Executive Vice President
Elizabeth Masson Hurlburt
Other
Thomas Nusbickel
Director
Joseph Todisco
Independent Director
Paulo Costa
Independent Director
Janet Dillione
Independent Director
Gregory Duncan
Independent Director
Alan Dunton
Independent Director
Steven Lefkowitz
No Data
No Data
About CRMD
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's primary focus is on the development of its product candidate, DefenCath. The Company has in-licensed the rights to develop and commercialize its product candidate DefenCath. The DefenCath is a novel anti-infective solution intended for the reduction of catheter-related infections in patients requiring central venous catheters in clinical settings such as hemodialysis, total parenteral nutrition, and oncology. DefenCath product is available in Europe and other territories under the brand name Neutrolin.

Webull offers kinds of CorMedix Inc. stock information, including NASDAQ:CRMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRMD stock methods without spending real money on the virtual paper trading platform.